Biomanufacturing for clinically advanced cell therapies
Name
nihms-1028672.pdf
Description
Accepted version
Size
1.63 MB
Format
Adobe PDF
Checksum (MD5)
049be2c72fba4899a372e24707029334
Author(s)
Aijaz, Ayesha
Li, Matthew
Smith, David
Khong, Danika
LeBlon, Courtney
Olabisi, Ronke M.
Libutti, Steven
Tischfield, Jay
Maus, Marcela V.
Deans, Robert
Date Issued
June 2018
Journal
Nature Biomedical Engineering
Publisher
Springer Science and Business Media LLC
Citation
Aijaz, Ayesha et al. "Biomanufacturing for clinically advanced cell therapies." Nature Biomedical Engineering 2, 6 (June 2018): 362–376 © 2018 The Author(s)
Version
Author's final manuscript
Abstract
The achievements of cell-based therapeutics have galvanized efforts to bring cell therapies to the market. To address the demands of the clinical and eventual commercial-scale production of cells, and with the increasing generation of large clinical datasets from chimeric antigen receptor T-cell immunotherapy, from transplants of engineered haematopoietic stem cells and from other promising cell therapies, an emphasis on biomanufacturing requirements becomes necessary. Robust infrastructure should address current limitations in cell harvesting, expansion, manipulation, purification, preservation and formulation, ultimately leading to successful therapy administration to patients at an acceptable cost. In this Review, we highlight case examples of cutting-edge bioprocessing technologies that improve biomanufacturing efficiency for cell therapies approaching clinical use.
MIT Department
Massachusetts Institute of Technology. Department of Chemical Engineering
Massachusetts Institute of Technology. Institute for Medical Engineering & Science
Harvard University--MIT Division of Health Sciences and Technology
Koch Institute for Integrative Cancer Research at MIT
Terms of Use
Creative Commons Attribution-Noncommercial-Share Alike
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1038/s41551-018-0246-6
